113 related articles for article (PubMed ID: 10929591)
21. [Malignant lymphoma of the skin].
Nakajima H; Miyamoto H
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1735-43. PubMed ID: 3876074
[TBL] [Abstract][Full Text] [Related]
22. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas.
Sarris AH; Daliani D; Ulmer R; Crow M; Broxmeyer HE; Reiss M; Karasavvas N; Zelenetz AD; Pugh W; Cabanillas F; Deisseroth AB; Duvic M
Clin Cancer Res; 1997 Feb; 3(2):169-77. PubMed ID: 9815669
[TBL] [Abstract][Full Text] [Related]
23. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
24. T-cell technology in the diagnosis & management of cutaneous T-cell lymphoma.
Duncan KO; Heald PW
Compr Ther; 1998 Mar; 24(3):117-22. PubMed ID: 9559245
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis of cutaneous T-cell lymphoma.
Toback AC; Edelson RL
Dermatol Clin; 1985 Oct; 3(4):605-14. PubMed ID: 2878753
[TBL] [Abstract][Full Text] [Related]
26. [Therapy of cutaneous T-cell lymphomas].
Rappersberger K; Ortel B; Forstinger C; Wolff K
Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
[TBL] [Abstract][Full Text] [Related]
27. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
28. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death.
Klemke CD; Brenner D; Weiss EM; Schmidt M; Leverkus M; Gülow K; Krammer PH
Cancer Res; 2009 May; 69(10):4175-83. PubMed ID: 19435902
[TBL] [Abstract][Full Text] [Related]
29. [Current therapy concepts in cutaneous T-cell lymphomas].
Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
[TBL] [Abstract][Full Text] [Related]
30. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
31. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
33. [Skin memory: the clinical implications].
Gaide O
Rev Med Suisse; 2016 Mar; 12(512):631-4. PubMed ID: 27172692
[TBL] [Abstract][Full Text] [Related]
34. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases.
Beltraminelli H; Leinweber B; Kerl H; Cerroni L
Am J Dermatopathol; 2009 Jun; 31(4):317-22. PubMed ID: 19461234
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous T-cell lymphoma sparing resolving dermatomal herpes zoster lesions: an unusual phenomenon and implications for pathophysiology.
Twersky JM; Nordlund JJ
J Am Acad Dermatol; 2004 Jul; 51(1):123-6. PubMed ID: 15243537
[TBL] [Abstract][Full Text] [Related]
37. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy.
Jones D; Ibrahim S; Patel K; Luthra R; Duvic M; Medeiros LJ
Clin Cancer Res; 2004 Aug; 10(16):5587-94. PubMed ID: 15328201
[TBL] [Abstract][Full Text] [Related]
38. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
39. [The cutaneous lymphocyte antigen. New realization of pathogenic T-cell mediated skin diseases].
Hautarzt; 1997 Dec; 48(12):949. PubMed ID: 9486373
[No Abstract] [Full Text] [Related]
40. Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells.
Picker LJ; Treer JR; Ferguson-Darnell B; Collins PA; Bergstresser PR; Terstappen LW
J Immunol; 1993 Feb; 150(3):1122-36. PubMed ID: 7678617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
